Measures Overview

ASCO’s Quality Oncology Practice Initiative (QOPI®) provides the necessary tools for oncology practices to routinely and reliably assess care, improve outcomes, and bring higher value to patients with cancer. ASCO appreciates the challenge to provide quality care to patients, while also needing to control costs and meet federal reimbursement guidelines.  By participating in ASCO’s QOPI Program practices can identify areas for improvement, benchmark improvement results against a national aggregate, and keep current with national practice guidelines. QOPI also contributes to the performance improvement assessment of ABIM MOC Part IV, PICME activities, and fellowship program engagement of fellows in assessment and improvement activities.

At the core of the QOPI Program is robust library of quality measures developed by oncologists and quality experts and founded on ASCO and nationally recognized practice guidelines and expert consensus. The more than180 measures reflect the team-based care provided to the patient with cancer in the outpatient oncology setting.

View QOPI's Measures by Reporting Pathway Here. If any Questions or Requests for QOPI Measures in Excel Format, please feel free to contact the QOPI Help Desk

QOPI Measures Overview Accordion

QOPI Measures Development

At the core of the QOPI Program is a robust library of quality measures developed by oncologists and quality experts and founded on ASCO and nationally recognized practice guidelines along with expert consensus. The more than180 measures reflect the team-based care provided to the patient with cancer in the outpatient oncology setting.

  • The ASCO Measures Task Force (MTF) of the ASCO Quality of Care Committee oversees the development, maintenance, testing, and validation of measures for ASCO.
  • The MTF collaborates internally with ASCO Guideline panels and externally with sister societies as well as key stakeholders to develop and adapt measures appropriate for the oncology setting. 
  • The MTF is working to develop a number of new measures to help bring value to members who would like to integrate QOPI to meet their quality assessment and reporting needs.
  • If you have suggestions for the MTF, you may contact the staff lead, August Knape at August.Knape@ASCO.Org.

When new measures are integrated into QOPI, they are offered as ‘Test’ measures and remain as such for several reporting periods.  During the testing phase, feedback and comments are collected and reviewed and the measure performance is evaluated for face and construct validity.  Adjustments or modifications may be made during this testing period to the data elements collected and/or the measure specifications to ensure the measure is accurately assessing what is intended.

QOPI Measures Categorizations

The QOPI Measures are categorized by modules (a grouping of like measures) and pathways (a grouping of different measures) to provide a comprehensive view of the cancer patient experience and to help practices meet their reporting needs.

Image of QOPI Measures by Module Table

 

Types of QOPI Measures Offered
  • Percentage or Performance rate: Measure that reports the number of eligible cases for the measure divided by the number of cases that met the criteria being assessed.
  • Combined:  Measure in which either of the two individual measures within the combined measure is met.

For example:  

Core 16 - Patient consent for chemotherapy (combined measure, 14 or 15), if there is either a signed consent in the chart or there is a practitioner’s notation that the patient consented for chemotherapy, the chart counts as “passing” the measure

  • Defect-Free: A measure in which a chart must have met the criteria for all measures for which it applies within the defect-free measure set.

For example:

For a chart to pass Core 6 - Pain addressed appropriately (defect-free measure, 3, 4, and 5) the chart would have to have evidence of all of the following:

Core 3 - Pain assessed by second visit to office

Core 4- If pain was noted for this patient, then the pain was quantified

Core 5 - If moderate/severe pain was noted for this patient, then there was a plan to address the pain

OR

Pain assessed by second visit to office, patient did not have pain.

  • Over-use (Lower Score – Better): Procedures and/or treatments whose common use and clinical value are not supported by available evidence.

For example:

 Don’t perform surveillance testing (biomarkers) or imaging (PET, CT, and radionuclide bone scans) for asymptomatic individuals who have been treated for breast cancer with curative intent.

Breast 62a: PET, CT, or radionuclide bone scan within 3 months after diagnosis of stage I, IIA, or IIB breast cancer (Lower Score - Better) (Test Measure - Top 5)

Breast 62c:  Serum tumor marker surveillance within 12 months after diagnosis of breast cancer in patients who received treatment with curative intent (Lower Score - Better) (Test Measure Top 5)

QCP Measures

Module

#

Measure

Core

1

Pathology report confirming malignancy*  

Core

2

Staging documented within one month of first office visit*                                              
NQF Endorsed #0386 (adapted)

Core

6

Pain addressed appropriately (defect-free measure, 3, 4a, and 5)*                                 
NQF Endorsed #0383 (adapted) 

Core

9

Documented plan for chemotherapy, including doses, route, and time intervals*

Core

10

Chemotherapy intent (curative vs. non-curative) documented before or within two weeks after administration *

Core

21a

Smoking status/tobacco use documented in past year *
NQF Endorsed #0028 (adapted)

Core

24

Patient emotional well-being assessed by the second office visit*

Symptom

27

Corticosteroids and serotonin antagonist prescribed with moderate/high emetic risk chemotherapy*

Symptom

33

Infertility risks discussed prior to chemotherapy with patients of reproductive age*

EOL

38

Pain addressed appropriately (defect-free measure, 35, 36a, and 37)*           
NQF Endorsed #0383/#0384 (adapted)

EOL

45a

Hospice enrollment and enrolled more than 7 days before death (defect-free measure, 42 and inverse 45)*
 NQF Endorsed #0216 (adapted)        

 

Breast

53

Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage I (T1c) to III ER/PR negative breast cancer**                                                                                                   
NQF Endorsed #0559 (adapted)

 

Breast

54

Test for Her-2/neu overexpression or gene amplification*                                       
NQF Endorsed #1878 (adapted)

Breast

56a

Trastuzumab not received when Her-2/neu is negative or undocumented (inverse of 56 )*
NQF Endorsed #1857 (adapted)

Breast

57

Trastuzumab received by patients with AJCC stage I (T1c) to III Her-2/neu positive breast cancer**
NQF Endorsed #1858 (adapted)

Breast

59

Tamoxifen or AI received within 1 year of diagnosis by patients with AJCC stage I (T1c) to III ER or PR positive breast cancer**                                                                                                                          
NQF Endorsed #0220/#0387 (adapted) 

Colorectal

66

CEA within 4 months of curative resection for colorectal cancer*

 

Colorectal

68

Adjuvant chemotherapy received within 4 months of diagnosis by patients with AJCC stage III colon cancer**
NQF Endorsed #0223/#0385 (adapted)

 

Colorectal

72

Adjuvant chemotherapy received within 9 months of diagnosis by patients with AJCC stage II or III rectal cancer**

Colorectal

73

Colonoscopy before or within 6 months of curative colorectal resection or completion of primary adjuvant chemotherapy*                                                                                                                                     
NQF Endorsed #0572 (adapted)

Colorectal

74

KRAS testing for patients with metastatic colorectal cancer who received anti-EGFR MoAb therapy*
NQF Endorsed #1859 (adapted)

Colorectal

75a

Anti-EGFR MoAb therapy not received by patients with KRAS mutation (Inverse of 75 )*
NQF Endorsed #1860 (adapted)

 

NSCLC

81

Adjuvant cisplatin-based chemotherapy received within 60 days after curative resection by patients with AJCC stage II or IIIA NSCLC**

NSCLC

84

Performance status documented for patients with initial AJCC stage IV or distant metastatic NSCLC*

NSCLC

85

Platinum doublet first-line chemotherapy or EGFR-TKI (or other targeted therapy with documented DNA mutation) received by patients with initial AJCC stage IV or distant metastatic NSCLC with performance status of 0-1 without prior history of chemotherapy*

NSCLC

88

Positive  mutation for patients with stage IV NSCLC who received first-line EGFR tyrosine kinase inhibitor or other targeted therapy*

 

Learn more on the QOPI Certification Measures page.